Healthcare - Press Releases

American Lung Association report examines the use of satellite-derived data to track unhealthy levels of NO

ROCKVILLE, Md., 6 mars 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), un partenaire de dveloppement de traitements de pointe du gne aux BPF, a annonc aujourd'hui la nomination de John Chiminski et de Karen Flynn en tant que membres non excutifs de son conseil d'administration. John sera le prsident du conseil d'administration et EW Healthcare Partners a dsign Karen pour siger au conseil d'administration de la socit en tant que l'un de ses reprsentants. Leur leadership et leur expertise approfondie du secteur seront essentiels pour permettre Ascend de renforcer ses capacits et de se positionner en vue de la croissance.

BARCELONA, Spain, March 6, 2025 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, together with China Unicom and YunHuan Technology, has been awarded the "Best Mobile Innovation for Cities" for their innovative "5G-A Smart City Low-Altitude Blood Delivery" project at the Global Mobile (GLOMO) Awards during MWC Barcelona 2025. The award recognizes their joint efforts in pioneering the commercial deployment of 5G-A Integrated Sensing and Communication technology in urban blood delivery.

LINKPING, Sweden, March 6, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that a US health system will expand its use of Sectra's enterprise imaging solution with digital pathology. The digital solution will enhance diagnostic speed by enabling pathologists to review and collaborate on cases more effectively. Moreover, using the same system to store and view images and information from various medical specialties enables integrated diagnostics, which is key for efficient cancer care.

SHANGHAI, March 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been dosed with the Company's internally developed personalized mRNA cancer vaccine EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT) EVM16CX01. EVM16CX01 is the first-in-human (FIH) trial for EVM16, conducted jointly at Peking University Cancer Hospital and Fudan University Shanghai Cancer center, to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody in patients with advanced or recurrent solid tumors.

BARCELONA, Spain, March 6, 2025 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, together with China Unicom and YunHuan Technology, has been awarded the "Best Mobile Innovation for Cities" for their innovative "5G-A Smart City Low-Altitude Blood Delivery" project at the Global Mobile (GLOMO) Awards during MWC Barcelona 2025. The award recognizes their joint efforts in pioneering the commercial deployment of 5G-A Integrated Sensing and Communication technology in urban blood delivery.

SUZHOU, China, March 6, 2025 /PRNewswire/ -- On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has received clearance from the U.S Food and Drug Administration(FDA) for its Investigational New Drug (IND) application for GEN6050X, a first-in-class base editing drug for Duchenne Muscular Dystrophy (DMD). GenAssist is planning to conduct clinical study globally for GEN6050X.

The Alliance for Women's Health & Prevention (PRNewsfoto/Alliance for Women's Health & Prevention) The EveryBODY Covered campaign logo. (PRNewsfoto/Alliance for Women's Health & Prevention)

EMERYVILLE, Calif., March 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Exchange Agreements") with a limited number of holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the "2026 Notes") and one new investor, pursuant to which the Company will issue $225 million aggregate principal amount of 2.0% Convertible Senior Notes due 2030 (the "New Notes") comprised of (i) an exchange for the retirement of approximately $185 million in aggregate principal amount of existing 2026 Notes, and (ii) approximately $40 million of New Notes issued to existing holders and one new investor (the "Transactions").

Star athletes on the squad includeJohni Broome, Mark Sears, Madison Booker, and Lauren Betts

RF-Cyber C-UAS Category Leader Bolsters Counter-Drone Market Presence with U.K. Office and Expert Team to Support Rapid Country Growth and Strengthen Customer Engagement

PORTLAND, Ore., March 6, 2025 /PRNewswire/ -- Calling all medical students drowning in UWorld questions, buried under Anki decks, and second-guessing every NBME score-there's a new way to conquer USMLE Step 1 without the burnout, the panic, or the caffeine-induced existential crises. Introducing Step 1000, a high-yield, anxiety-free study system designed to make Step 1 prep sustainable, structured, and-dare we say-actually enjoyable.

ALD enables lead-free MCP production with precise thin-film deposition, enhancing manufacturing yields, device performance, and lifetime value. Exosens chose Beneq's P400A batch and TFS 500 ALD systems for their scalability, precision, and ability to support development from R&D to production.

ALD enables lead-free MCP production with precise thin-film deposition, enhancing manufacturing yields, device performance, and lifetime value. Exosens chose Beneq's P400A batch and TFS 500 ALD systems for their scalability, precision, and ability to support development from R&D to production.

Milestone Commemorated with Savings for Prep and Exam Purchases

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.

-Ascend Advanced Therapies nombra a John Chiminski como presidente y a Karen Flynn como directora independiente

NEW YORK, March 5, 2025 /PRNewswire/ --Lucid Diagnostics Inc.(Nasdaq: LUCD)("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share.

Tampa General Hospital Cancer Institute hosted a day of keynotes, presentations and discussions at TGH Brooksville to address the challenges facing cancer patients in rural communities.

CHICAGO, March 5, 2025 /PRNewswire/ -- TheRobert Spadoni Scholarship for Entrepreneurs is now accepting applications from undergraduate students nationwide who demonstrate exceptional entrepreneurial potential. Established by healthcare executive Robert Spadoni, this $1,000 scholarship supports students committed to creating positive change through entrepreneurial ventures.

DURHAM, N.C., March 5, 2025 /PRNewswire/ --Pluto Health, a Duke-University spin-out, is now a qualified Medicaid provider in TN. The company integrates care delivery with its proprietary platform that leverages AI and data science to deliver convenient care options and health services for patients. This milestone strengthens Pluto Health's commitment to delivering comprehensive, accessible, and high-quality care to patients across the state, particularly those in underserved communities.

WASHINGTON, March 5, 2025 /PRNewswire/ --Paralyzed Veterans of AmericaChief Executive Officer Carl Blake releases statement following the leak of an internal memorevealing the Department of Veterans Affairs' plan to reduce its overall staffing of the department to FY 2019 levels - a decrease of more than 80,000 positions from the current staffing level.

With global cancer incidence rising and a strong clinical pipeline exploring combination therapies, the XPOVIO addressable market is expanding. Despite competition from CAR-T and novel therapies, XPOVIO's oral administration and unique mechanism offer differentiation.

The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and development of innovative interferon therapies are key factors fueling the expansion of the interferon market from 2025 to 2032.

SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.